Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07065058

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

A Phase I, Single-Center, Open-Label, Single-Arm, Fixed-Sequence Clinical Study to Evaluate the Pharmacokinetic Interactions of VCT220 With Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

Sponsor: Vincentage Pharma Co., Ltd

Conditions Obesity &Amp; Overweight

Interventions Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

Updated 2 times since 2025 Last updated: Aug 12, 2025 Started: Jul 1, 2025 Primary completion: Oct 31, 2025 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Obesity &Amp; Overweight, this trial is ongoing. The trial is conducted by Vincentage Pharma Co., Ltd and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1

First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vincentage Pharma Co., Ltd

Data source: Vincentage Pharma Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China